Ptc Therapeutics (PTCT) Income from Continuing Operations (2012 - 2026)

Ptc Therapeutics' Income from Continuing Operations history runs 15 years deep, the most recent figure standing at 83496000.0 for Q2 2026.

• In Q2 2026, Income from Continuing Operations rose 228.75% year-over-year to 83496000.0; the TTM figure through Jun 2026 stood at 382501000.0 (up 4.26% YoY), while the FY2025 annual figure was 1103527000.0, up 276.39% from the prior year.
• Income from Continuing Operations for Q2 2026 stood at 83496000.0, up from 2809000.0 in the prior quarter.
• The five-year high for Income from Continuing Operations was 866562000.0 in Q1 2025, with the low at 328196000.0 in Q4 2024.
• The 5-year median for Income from Continuing Operations is 107984500.0 (2022), against an average of 39960277.78.
• The sharpest annual moves came in 2025 and 2026: Income from Continuing Operations surged 1046.28% in 2025, then sank 100.32% in 2026.
• Ptc Therapeutics' Income from Continuing Operations stood at 174528000.0 in 2022, then sank by 40.05% to 244426000.0 in 2023, then sank by 34.27% to 328196000.0 in 2024, then surged by 187.12% to 285918000.0 in 2025, then plunged by 70.8% to 83496000.0 in 2026.
• Business Quant data shows PTCT's Income from Continuing Operations at 83496000.0 in Q2 2026, 2809000.0 in Q1 2026, and 285918000.0 in Q4 2025.